BG
HCAT icon

Bellevue Group’s Health Catalyst HCAT Stock Holding History

Bellevue Group’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-424,611
Closed -$6.15M – 179
2022
Q2 		$6.15M Hold
424,611
– – 0.09% 109
2022
Q1 		$11.1M Sell
424,611
-268,055
-39% -$7.61M 0.13% 104
2021
Q4 		$27.4M Sell
692,666
-34,567
-5% -$1.58M 0.28% 91
2021
Q3 		$36.4M Sell
727,233
-26,388
-4% -$1.44M 0.37% 84
2021
Q2 		$41.8M Buy
753,621
+11,766
+2% +$627K 0.41% 77
2021
Q1 		$34.7M Buy
741,855
+121,645
+20% +$5.89M 0.37% 84
2020
Q4 		$27M Buy
620,210
+98,314
+19% +$3.63M 0.31% 85
2020
Q3 		$19.1M Buy
521,896
+172,727
+49% +$5.87M 0.26% 91
2020
Q2 		$10.2M Buy
349,169
+96,169
+38% +$2.66M 0.14% 108
2020
Q1 		$6.62M Buy
253,000
+28,492
+13% +$871K 0.13% 105
2019
Q4 		$7.79M Buy
224,508
+64,292
+40% +$2.13M 0.12% 102
2019
Q3 		$5.07M Buy
+160,216
New +$6.31M 0.09% 109

Other funds holding HCAT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group's HCAT Position: Q3 2022 in Review

Bellevue Group sold out of Health Catalyst (HCAT) in Q3 2022, closing a stake of 424,611 shares — an estimated $6.15M sold.

Bellevue Group first reported a position in HCAT in Q3 2019 and held it in 12 quarters. The position peaked at $41.8M in Q2 2021. 171 funds tracked by Wall St. Rank hold HCAT as of Q3 2022.

  • Bellevue Group reported no remaining Health Catalyst position as of Q3 2022 after selling out during the quarter.
  • Bellevue Group sold 424,611 Health Catalyst shares in Q3 2022, an estimated $6.15M.
  • Bellevue Group first reported a position in Health Catalyst in Q3 2019 and held it in 12 quarters.
  • Bellevue Group's Health Catalyst position peaked at $41.8M in Q2 2021.
  • 171 funds tracked by Wall St. Rank held Health Catalyst as of Q3 2022.

Based on Bellevue Group's 13F filing for Q3 2022, filed 14 Nov 2022.